Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - piracetamum - filmtabletten - piracetamum 1200.00 mg, macrogolum 6000, silica colloidalis anhydrica, magnesii stearas, carmellosum natricum conexum corresp. natrium max. 3.75 mg, pellicule: hypromellosum, e 171, macrogolum 400, macrogolum 6000, pro compresso obducto. - nootropikum - synthetika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - piracetamum - solution buvable 333.3 mg/ml - piracetamum 333.3 mg, glycerolum (85 per centum) 270.0 mg, e 218 1.8 mg, propylis parahydroxybenzoas 0.2 mg, natrii acetas trihydricus corresp. natrium 0.3377 mg, acidum aceticum glaciale, aqua purificata q.s. ad solutionem pro 1 ml. - nootropikum - synthetika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - certolizumabum pegolum - injektionslösung in einem fertigpen - certolizumabum pegolum 200 mg, natrii acetas, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.257 mg. tela cum: alcohol isopropylicus. - morbus crohn, rheumatoider arthritis, psoriasis-arthritis, - röntgenologischer axialer spondyloarthritis, einschließlich spondyloarthrite spondylitis und axiale spondyloarthritis ohne radiologische zeichen, plaque-psoriasis bei erwachsenen - biotechnologika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - hydroxyzini hydrochloridum - filmtabletten - hydroxyzini hydrochloridum 25 mg, lactosum monohydricum 54.8 mg, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, pellicule: hypromellosum, macrogolum 400, e 171 pro compresso obducto. - beruhigungsmittel, antihistaminikum - synthetika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - hydroxyzini hydrochloridum - sirup - hydroxyzini hydrochloridum 25 mg, ethanolum 96 per centum 12.5 mg, saccharum 9.375 g, aqua purificata, levomentholum, aromatica, e 211 3.75 mg corresp. natrium 0.598 mg ad solutionem pro 12.5 ml. - sedativum, antihistaminikum - synthetika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - solution injectable en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - injektionslösung in einem fertigpen - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - eisen - gélules à libération modifiée - ferrum 100 mg ut ferrosi glycinatis sulfas ut ferrosi sulfas heptahydricus et glycinum, e 300, cellulosum microcristallinum, hypromellosum, hydroxypropylcellulosum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas, polysorbatum 80, triethylis acetylcitras, talcum, matériel de la capsule: gelatina, e 171, e 172 (rubrum), e 172 (nigrum), e 172 (flavum), pro capsula corresp. natrium 0.0239 mg. - eisenmangelanämie erwiesen - synthetika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - romosozumabum - injektionslösung in einem fertigpen - romosozumabum 105 mg, calcii acetas, saccharum, polysorbatum 20, natrii hydroxidum ad ph, aqua ad iniectabile ad solutionem pro 1.17 ml. - traitement de l'ostéoporose grave chez les femmes après la ménopause - biotechnologika

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - romosozumabum - solution injectable en seringue préremplie - romosozumabum 105 mg, calcii acetas, saccharum, polysorbatum 20, natrii hydroxidum ad ph, aqua ad iniectabile q.s. ad solutionem pro 1.17 ml. - traitement de l'ostéoporose grave chez les femmes après la ménopause - biotechnologika